[Management of glucocorticoid-induced osteoporosis].
Osteoporosis is the most frequent adverse effect observed during glucocorticoids therapy. The 2004 edition of the guideline on the management and treatment of glucocorticoid-induced osteoporosis has been proposed by The Japanese Society for Bone and Mineral Research. The subjects were patients with using or planning to use oral glucocorticoids for 3 months or longer. The criterion for starting treatment consisted patients with prior fragility fracture and with new fractures during treatment, patients with less BMD than %YAM80, and patients with using as a dose of 5 mg/day or higher (mean daily dose) as prednisolone equivalent. The Bisphosphonates have been recommended as first-line drugs. Active vitamin D3 and vitamin K2 have been recommended as second-line drugs.
Soen
Satoshi
S
Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kinki University School of Medicine, USA.
D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism; D002762:Cholecalciferol / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage*; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D015675:Osteocalcin / Q000378:metabolism; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011239:Prednisolone / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D024482:Vitamin K 2 / Q000008:administration & dosage
D004164:Diphosphonates; D005938:Glucocorticoids; D015675:Osteocalcin; D024482:Vitamin K 2; D002762:Cholecalciferol; D011239:Prednisolone